Compared with non-targeted nanovaccines, CD40-targeted ones notably enhanced E7-specific CD8+ T-cells, leading to tumor growth suppression.58 Incorporation of antibodies and ligands on nano-sized vaccines can target APCs, such as DCs, for enhancing their therapeutic efficacy. The gene discussed is CD8A; the disease is neoplasm.